Literature DB >> 8006361

Childhood pseudotumor cerebri: clinical and intracranial pressure response to acetazolamide and furosemide treatment in a case series.

J F Schoeman1.   

Abstract

The purpose of this study was to investigate the efficacy of combined therapy with acetazolamide and furosemide in normalizing intracranial pressure in children with pseudotumor cerebri. The role of repeated lumbar cerebrospinal fluid pressure monitoring in evaluating the response to therapy is also demonstrated. Continuous 1-hour lumbar cerebrospinal fluid pressure monitoring was done in eight children with pseudotumor cerebri on admission and at weekly intervals until the baseline pressure had normalized. (One child had two episodes of pseudotumor cerebri). All patients were treated with oral acetazolamide and furosemide until papilledema had cleared. Raised intracranial pressure was present on admission in all nine episodes of pseudotumor cerebri. Six children had an increased baseline cerebrospinal fluid pressure, whereas raised intracranial pressure was diagnosed in three children on account of an abnormal pulse wave and/or pressure waves. The mean baseline pressure was significantly lower after the 1st week of treatment than on admission (P = .007) and normalized in all patients within 6 weeks of start of therapy. All children had a rapid clinical response. Combined therapy with acetazolamide and furosemide is an effective first-line method of treating raised intracranial pressure in children with pseudotumor cerebri. The good correlation found between the clinical response and normalization of baseline cerebrospinal fluid pressure suggests that clinical monitoring of treatment is adequate in most children with this condition.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8006361     DOI: 10.1177/088307389400900205

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  14 in total

1.  Idiopathic Intracranial Hypertension.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-03       Impact factor: 3.598

2.  Idiopathic intracranial hypertension in children: Diagnostic and management approach.

Authors:  Abdulrahman Albakr; Muddathir H Hamad; Ali H Alwadei; Fahad A Bashiri; Hamdy H Hassan; Hiyam Idris; Saeed Hassan; Taim Muayqil; Ikhlass Altweijri; Mustafa A Salih
Journal:  Sudan J Paediatr       Date:  2016

Review 3.  Update on the Diagnosis and Treatment of Idiopathic Intracranial Hypertension.

Authors:  Sarah R Ahmad; Heather E Moss
Journal:  Semin Neurol       Date:  2019-12-17       Impact factor: 3.420

4.  Idiopathic Intracranial Hypertension.

Authors:  Robert K. Shin; Laura J. Balcer
Journal:  Curr Treat Options Neurol       Date:  2002-07       Impact factor: 3.598

5.  Acetazolamide and corticosteroid therapy in complicated arachnoid cyst.

Authors:  Pierluigi Longatti; Elisabetta Marton; Domenico Billeci
Journal:  Childs Nerv Syst       Date:  2005-06-14       Impact factor: 1.475

Review 6.  Update on Idiopathic Intracranial Hypertension.

Authors:  Sivashakthi Kanagalingam; Prem S Subramanian
Journal:  Curr Treat Options Neurol       Date:  2018-05-28       Impact factor: 3.598

7.  Use of acetazolamide to decrease cerebrospinal fluid production in chronically ventilated patients with ventriculopleural shunts.

Authors:  E Carrion; J H Hertzog; M D Medlock; G J Hauser; H J Dalton
Journal:  Arch Dis Child       Date:  2001-01       Impact factor: 3.791

Review 8.  Headache and the pseudotumor cerebri syndrome.

Authors:  Robert M Mallery; Deborah I Friedman; Grant T Liu
Journal:  Curr Pain Headache Rep       Date:  2014-09

9.  Idiopathic intracranial hypertension (pseudotumor cerebri): recognition, treatment, and ongoing management.

Authors:  Matthew J Thurtell; Michael Wall
Journal:  Curr Treat Options Neurol       Date:  2013-02       Impact factor: 3.598

Review 10.  Non-traumatic pediatric intracranial hypertension: key points for different etiologies, diagnosis, and treatment.

Authors:  Nir Shimony; Meleine Martinez-Sosa; Brooks Osburn; George I Jallo
Journal:  Acta Neurol Belg       Date:  2021-04-07       Impact factor: 2.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.